Useful Online Resources and Clinical Trials for Ovarian Cancer
Survivors Tell “Stories of Hope”
“Stories of Hope—Surviving Ovarian Cancer” is a 15-minute video documentary featuring the stories of 5 women who have made the difficult journey of survival. Representing different generations and ethnic backgrounds, the women provide information, encouragement, and hope. The program is among a variety of videos the National Ovarian Cancer Coalition–Sacramento Chapter has produced along with Blaise Media to support the national “Break the Silence” campaign intended to increase awareness of ovarian cancer.
Racing Against Time
The 7th Annual Teal Ribbon 5k Race Against Time is set for Sunday, May 29, in Philadelphia. Sponsored by the Ovarian Cancer Research Foundation Inc, the event will begin at the Please Touch Museum in Fairmount Park. In the past, teams have participated in honor or memory of a loved one affected by ovarian cancer. Runners can register online until May 28 or on the morning of the race. Activities begin at 8 AM with the run, followed by a walk and a children’s fun run.
Making the Best of PARP Inhibitors in Ovarian Cancer
EXPIRES: Aug. 10, 2011
The goal of this activity, intended for gynecologists, oncologists, and other physicians who care for women with ovarian cancer, is to describe how poly(ADPribose) polymerase (PARP) inhibitors may be used to treat ovarian cancer.
Participants will learn to distinguish characteristics of BRCA-associated ovarian cancer, identify how BRCA mutations affect the response to therapy for advanced ovarian cancer, and describe the efficacy and safety of PARP inhibitors in the treatment of ovarian cancer on the basis of recent research, including limitations in current studies.
The Effect of TRA-8 on Ovarian Cancer Tissue
STUDY TYPE: Observational
AGE/SEX REQUIREMENTS: ≥19 years (women)
SPONSOR: University of Alabama at Birmingham
CLINICALTRIALS.GOV IDENTIFIER: NCT00711932
PURPOSE: This study’s goal is to determine the apoptosis- inducing efficacy of TRA-8 in patient ovarian cancer tissues using tissue-slice technology. Investigators also want to evaluate the expression of apoptosis regulatory proteins using multiplex proteomic technology and its correlation with TRA-8-induced cytotoxicity in patient ovarian cancer tissues. Patients must have suspected ovarian cancer and must be a candidate for surgery. They must also have an extra tumor at the time of surgery that is appropriate for slicing. Patients who have received any prior therapy for ovarian cancer are not eligible. Estimated completion date is January 2013.